Wu Chengde, Liang Ying, Fu Fangyong
Department of Thoracic Surgery, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, China.
Evid Based Complement Alternat Med. 2022 Aug 5;2022:2832739. doi: 10.1155/2022/2832739. eCollection 2022.
The aim of this study is to evaluate the effect of Shenqi fuzheng injection on leukopenia and T-cell subsets in patients with non-small cell lung cancer (NSCLC) undergoing radiotherapy.
A total of 124 patients with advanced NSCLC treated in the oncology department of our hospital from January 2017 to January 2019 were included and assigned at a ratio of 1 : 1 to receive conventional radiotherapy (control group, = 62) or conventional radiotherapy plus Shenqi Fuzheng injection (study group, = 62) via the random number table method.
The study group showed a significantly higher objective response rate (ORR) and a lower incidence of leukopenia versus the control group ( < 0.05). After the treatment, Shenqi Fuzheng injection resulted in significantly lower levels of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) in the study group versus conventional treatment given to the control group. After the treatment, the control group showed significantly decreased ratios of CD3+ T cells, CD4+ T cells, and CD4+/CD8+, and an increased ratio of CD8+ T cells, and significant differences when compared with the study group. The T-cell subsets of the patients in the study group showed no significant changes than those between the treatment. The median OS was 20.0 months in the control group and 23.5 months in the study group. The differences between the two groups in terms of OS did not come up to the statistical standard.
Shenqi Fuzheng injection for NSCLC patients undergoing radiotherapy elevates the number of white blood cells, regulates T-cell immune function, reduces tumor markers, and enhances clinical efficacy. Further clinical trials are, however, required prior to clinical promotion.
本研究旨在评估参芪扶正注射液对接受放疗的非小细胞肺癌（NSCLC）患者白细胞减少及T细胞亚群的影响。
纳入2017年1月至2019年1月在我院肿瘤科治疗的124例晚期NSCLC患者，通过随机数字表法按1∶1比例分为两组，分别接受单纯常规放疗（对照组，n = 62）或常规放疗联合参芪扶正注射液治疗（研究组，n = 62）。
研究组的客观缓解率（ORR）显著高于对照组，白细胞减少发生率低于对照组（P < 0.05）。治疗后，研究组癌胚抗原（CEA）和神经元特异性烯醇化酶（NSE）水平显著低于对照组常规治疗。治疗后，对照组CD3 + T细胞、CD4 + T细胞及CD4 + /CD8 + 比值显著降低，CD8 + T细胞比值升高，与研究组相比差异有统计学意义。研究组患者治疗前后T细胞亚群无显著变化。对照组中位总生存期（OS）为20.0个月，研究组为23.5个月。两组OS差异未达到统计学标准。
参芪扶正注射液用于接受放疗的NSCLC患者可提高白细胞数量，调节T细胞免疫功能，降低肿瘤标志物，提高临床疗效。然而，在临床推广之前还需要进一步的临床试验。
